Five years ago, the Food and Drug Administration began implementing a plan to increase diversity and transparency in its clinical trials of medicines.
So what progress has been made? Well, not nearly enough, according to the reporting of Ed Silverman, a senior writer for STAT.
This article was originally published on WBUR.org.
Copyright 2022 NPR. To see more, visit https://www.npr.org.
